SG11201607627RA - Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis - Google Patents
Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosisInfo
- Publication number
- SG11201607627RA SG11201607627RA SG11201607627RA SG11201607627RA SG11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA SG 11201607627R A SG11201607627R A SG 11201607627RA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- preventing
- methods
- pulmonary fibrosis
- idiopathic pulmonary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/005—Enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461953438P | 2014-03-14 | 2014-03-14 | |
PCT/US2015/020263 WO2015138784A2 (en) | 2014-03-14 | 2015-03-12 | Compositions and methods for preventing or treating chronic lung allograft dysfunction (clad) and idiopathic pulmonary fibrosis (ipf) |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201607627RA true SG11201607627RA (en) | 2016-10-28 |
Family
ID=54067793
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607627RA SG11201607627RA (en) | 2014-03-14 | 2015-03-12 | Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis |
Country Status (12)
Country | Link |
---|---|
US (1) | US20150258192A1 (ko) |
EP (1) | EP3116543A4 (ko) |
JP (1) | JP6655547B2 (ko) |
KR (1) | KR20160124236A (ko) |
CN (1) | CN106456758A (ko) |
AU (1) | AU2015229251A1 (ko) |
BR (1) | BR112016021000A2 (ko) |
CA (1) | CA2942517A1 (ko) |
MX (1) | MX2016011852A (ko) |
RU (1) | RU2016140332A (ko) |
SG (1) | SG11201607627RA (ko) |
WO (1) | WO2015138784A2 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3352792B1 (en) * | 2015-09-25 | 2020-08-26 | Cedars-Sinai Medical Center | Targeting fibroblast invasion for pulmonary fibrosis |
WO2019070908A1 (en) | 2017-10-03 | 2019-04-11 | Cedars-Sinai Medical Center | METHODS OF TARGETING THE PD1 PATHWAY OF THE IMMUNE CONTROL POINT FOR THE TREATMENT OF PULMONARY FIBROSIS |
AU2019448236B9 (en) * | 2019-05-30 | 2024-07-11 | National Institute Of Biological Sciences, Beijing | Animal model of idiopathic pulmonary fibrosis, its construction method and use |
EP4185382A1 (en) * | 2020-07-24 | 2023-05-31 | Bristol-Myers Squibb Company | Methods of treating acute respiratory disorders |
CN112575074B (zh) * | 2020-10-09 | 2022-12-27 | 中山大学 | Nestin基因及蛋白在治疗器官纤维化中的应用 |
WO2022147172A1 (en) * | 2020-12-30 | 2022-07-07 | Briotech, Inc. | Methods and compositions of aqueous hypobromous acid for the treatment and prevention of inflammatory conditions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070280930A1 (en) * | 2004-03-17 | 2007-12-06 | Kasper Mathias Antoon Rouschop | Cd44-Targeting for Reducing/Preventing Ischemia-Reperfusion-Injury |
US7723336B2 (en) * | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
US20080199426A1 (en) * | 2007-01-11 | 2008-08-21 | Sukhatme Vikas P | Methods and compositions for the treatment and diagnosis of vascular inflammatory disorders or endothelial cell disorders |
DK2696888T3 (en) * | 2011-04-12 | 2019-03-25 | Moerae Matrix Inc | COMPOSITIONS AND METHODS FOR PREVENTION OR TREATMENT OF PULMONAL FIBROSE |
US10232039B2 (en) * | 2011-04-12 | 2019-03-19 | Duke University | Compositions and methods for the treatment of tissue fibrosis |
-
2015
- 2015-03-12 WO PCT/US2015/020263 patent/WO2015138784A2/en active Application Filing
- 2015-03-12 AU AU2015229251A patent/AU2015229251A1/en not_active Abandoned
- 2015-03-12 JP JP2016557276A patent/JP6655547B2/ja not_active Expired - Fee Related
- 2015-03-12 CN CN201580025482.9A patent/CN106456758A/zh active Pending
- 2015-03-12 SG SG11201607627RA patent/SG11201607627RA/en unknown
- 2015-03-12 CA CA2942517A patent/CA2942517A1/en not_active Abandoned
- 2015-03-12 RU RU2016140332A patent/RU2016140332A/ru not_active Application Discontinuation
- 2015-03-12 US US14/656,492 patent/US20150258192A1/en not_active Abandoned
- 2015-03-12 EP EP15761995.8A patent/EP3116543A4/en not_active Withdrawn
- 2015-03-12 KR KR1020167028395A patent/KR20160124236A/ko not_active Application Discontinuation
- 2015-03-12 BR BR112016021000A patent/BR112016021000A2/pt not_active Application Discontinuation
- 2015-03-12 MX MX2016011852A patent/MX2016011852A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2015138784A3 (en) | 2015-10-29 |
KR20160124236A (ko) | 2016-10-26 |
RU2016140332A3 (ko) | 2018-10-11 |
RU2016140332A (ru) | 2018-04-16 |
WO2015138784A2 (en) | 2015-09-17 |
CN106456758A (zh) | 2017-02-22 |
US20150258192A1 (en) | 2015-09-17 |
EP3116543A2 (en) | 2017-01-18 |
CA2942517A1 (en) | 2015-09-17 |
EP3116543A4 (en) | 2017-09-06 |
BR112016021000A2 (pt) | 2017-10-03 |
JP6655547B2 (ja) | 2020-02-26 |
AU2015229251A1 (en) | 2016-09-22 |
MX2016011852A (es) | 2017-05-09 |
JP2017509633A (ja) | 2017-04-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3496739T (pt) | Composições compreendendo polipéptidos actriia para uso no tratamento de hipertensão pulmonar | |
HK1249028A1 (zh) | 自發泡組合物和方法 | |
HK1252454A1 (zh) | 清潔組合物 | |
GB2546350B (en) | Compositions and methods | |
IL246383A0 (en) | Polyoxometalate and heteropolyoxometalate preparations and methods of using them | |
KR101830290B9 (ko) | 지방 유래 줄기세포로부터 추출된 엑소좀을 유효성분으로 포함하는 폐 섬유증 예방 또는 치료용 조성물 | |
GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
SG11201607627RA (en) | Compositions and methods for preventing or treating chronic lung allograft dysfunction and idiopathic pulmonary fibrosis | |
GB201417828D0 (en) | New methods and compositions | |
SG11201608128UA (en) | Polishing composition and polishing method | |
PL3256589T3 (pl) | Kompozycje i sposoby kontrolowania leptinotarsa | |
IL287983A (en) | 15-hepe or a preparation containing 15-hepe for the treatment or prevention of fibrosis | |
ZA201800219B (en) | Cleaning composition | |
PT3510167T (pt) | Métodos e composições para prever disfunção crónica de aloenxerto pulmonar | |
HK1244692A1 (zh) | 治療纖維化的方法 | |
ZA201700413B (en) | Flavor barrier composition | |
HUE050456T2 (hu) | Dimetil-amino-mikeliolid tüdõfibrózis kezelésében történõ alkalmazásra | |
ZA201802419B (en) | Hard surface cleaning composition | |
HK1244448A1 (zh) | 用於治療肺高血壓的方法 | |
ZA201901099B (en) | Compositions for the treatment of pulmonary fibrosis | |
PT3645735T (pt) | Métodos e composições para prever disfunção crónica de aloenxerto pulmonar | |
EP3610018A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PULMONARY FIBROSIS | |
EP3285794A4 (en) | METHODS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | |
EP3389715A4 (en) | COMPOSITIONS AND METHODS FOR TREATING CARDIAL DYSFUNCTION | |
EP3139912A4 (en) | Method of treating idiopathic pulmonary fibrosis |